ArticleJournal of computer-aided molecular design2025
Integrated strategy for screening direct Keap1-Nrf2 PPI inhibitors from traditional Chinese medicine: a case study of Achyranthis bidentatae Radix.
Article in Journal of computer-aided molecular design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Kaempferol Alleviates Aflatoxin B1-Induced Liver Injury by Mitigating Oxidative Stress.Nutrients · 2026Article
- A Principle-Guided Multistep Workflow for Screening Potential Quality Marker Candidates of Sanqi Shangyao Tablet Based on UHPLC-Q-Orbitrap MS, In Silico Screening, and In Vitro Validation.Biomedical chromatography : BMC · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Direct inhibition of the Kelch-like ECH-associated protein 1 (Keap1)-nuclear factor erythroid 2-related factor 2 (Nrf2) protein-protein interaction (PPI) represents a critical pathway for enhancing the antioxidant response. Therefore, screening for direct Keap1-Nrf2 PPI inhibitors holds significant potential for addressing oxidative stress-related diseases. This study aims to develop an integrated approach to identify direct Keap1-Nrf2 PPI inhibitors from traditional Chinese medicine (TCM) using Achyranthis bidentatae Radix (ABR) as a case study. The approach incorporated ultrahigh-performance liquid chromatography-quadrupole-orbitrap mass spectrometry analysis, data mining, drug-like property evaluation, molecular docking, chemical structure clustering, molecular dynamics (MD) simulations, in vitro experimental validation, and density functional theory (DFT) calculations. A total of 517 compounds were identified in ABR, of which 248 met the drug-likeness criteria. Additionally, seventeen compounds from six structural clusters were identified as having theoretical Keap1-Nrf2 PPI inhibitory activity. Among these compounds, shidasterone, nortrachelogenin, wogonin, and N-trans-feruloylmethoxytyramine were subjected to experimental evaluation for their Keap1-Nrf2 PPI inhibitory and free radical scavenging activities. MD simulations and DFT calculations demonstrated that these compounds directly inhibited Keap1-Nrf2 PPI through hydrophobic interactions, hydrogen bonds, and salt bridges. Moreover, DFT calculations confirmed that these compounds scavenged free radicals via the hydrogen atom transfer mechanism. In conclusion, the strategy presented herein offers a robust framework for screening direct Keap1-Nrf2 PPI inhibitors with structural diversity from ABR and other TCM sources.
Indexed as
Identifiers
40968251What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.